Skip to content
value.today

Tranzyme Inc.

Total raised
$50 M
3 rounds on record
Latest round
$28 M
Nov 2013
First round on record
Jun 2010
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Tranzyme Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2013$28 MNo. 3$10 to $50 million

Tranzyme Inc.: Raise no. 3, Nov 2013

Investors in this round

22 investors had bought by the notice of Nov 21, 2013: 22 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 10 investors are named for Tranzyme Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$28 M of $28 M offered
Smallest investment taken
no minimum stated
What was sold
equity, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,380,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • David S Moore · Executive Officer
  • Jeryl L Hilleman · Executive Officer
  • Anne M VanLent · Director
  • Eckard F Weber · Director
  • Franck S Rousseau · Director
  • Jean-Paul G Castaigne · Director
  • Lars G Ekman · Director
  • Linda S Grais · Director
  • Michael F Powell · Director
  • Nina L Kjellson · Director
  • Pratik F Shah · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Cowen & Company LLC (CRD 7616) · New York, New YorkSold in all US states
  • Stifel, Nicolaus & Company Incorporated (CRD 793) · St. Louis, MissouriSold in all US states

Remarks in the notice

  • On the use of proceeds: “The Issuer will use a portion of the gross proceeds for working capital and general corporate purposes, including payments to executive officers and directors in the ordinary course of business.”

Signed by Jeryl L. Hilleman, Chief Financial Officer and Secretary. Source: SEC Form D, newest notice filed Nov 21, 2013. Read the notice at the SEC.

equitySEC
Jul 2013$20 MNo. 2$10 to $50 million

Tranzyme Inc.: Raise no. 2, Jul 2013

Investors in this round

18 investors had bought by the notice of Jul 16, 2013: 18 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 10 investors are named for Tranzyme Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$20 M (amount offered: indefinite)
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
$5 million to $25 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dana S. McGowan · Executive Officer
  • David S. Moore · Executive Officer
  • Franck S. Rousseau · Executive Officer, Director
  • Linda S. Grais · Executive Officer, Director
  • Anne M. VanLent · Director
  • Eckard F. Weber · Director
  • Jean-Paul F. Castaigne · Director
  • Lars F. Ekman · Director
  • Michael F. Powell · Director
  • Nina S. Kjellson · Director
  • Pratik F. Shah · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Linda S. Grais, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 16, 2013. Read the notice at the SEC.

equitySEC
Jun 2010$2 MNo. 1$2 to $10 million

Tranzyme Inc.: Raise no. 1, Jun 2010

Investors in this round

1 investor had bought by the notice of Jun 24, 2010: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 10 investors are named for Tranzyme Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $3 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Richard I. Eisenstadt · Executive Officer
  • Vipin K. Garg · Executive Officer, Director
  • Aaron F. Davidson · Director
  • Alex D. Zisson · Director
  • Brenda D. Gavin · Director
  • David J. Drutz · Director
  • Donald F. Corcoran · Director
  • Jean-Paul K. Castaigne · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Richard I. Eisenstadt, Secretary. Source: SEC Form D, newest notice filed Jun 24, 2010. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Tranzyme Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2013).

    SEC Form D · Nov 2013

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Nov 2013

That is all the official record says: Tranzyme Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

10 named in official filings. Open an investor to see everything it has backed.

Investors in Tranzyme Inc.
InvestorKindAmountRoundRoleSource
BDC Capital Inc.Fund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2011)SEC Form 3
Capital regional et cooperatif DesjardinsFund or asset managernot statednot statedHeld preferred stock, 10% owner (Form 3, 2011)SEC Form 3
Hig GP II IncCompanynot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2011)SEC Form 3
H.I.G. Ventures - Tranzyme, LLCVenture capitalnot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2011)SEC Form 3
Quaker Bioventures Capital LPVenture capitalnot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2011)SEC Form 3
Quaker Bio Ventures LPVenture capitalnot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2011)SEC Form 3
Thomas, McNerney & Partners, LLCFund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2011)SEC Form 3
Thomas Mcnerney & Partners LPFund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2011)SEC Form 3
TMP Associates LPFund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2011)SEC Form 3
TMP Nominee, LLCOthernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2011)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 22 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Tranzyme Inc.
NameRoleNamed in
David S MooreExecutive officerNov 2013
Jeryl L HillemanExecutive officerNov 2013
Dana S. McGowanExecutive officerJul 2013
David S. MooreExecutive officerJul 2013
Franck S. RousseauExecutive officerJul 2013
Linda S. GraisExecutive officerJul 2013
Richard I. EisenstadtExecutive officerJun 2010
Vipin K. GargExecutive officerJun 2010
Anne M VanLentDirectorNov 2013
Eckard F WeberDirectorNov 2013
Franck S RousseauDirectorNov 2013
Jean-Paul G CastaigneDirectorNov 2013
Lars G EkmanDirectorNov 2013
Linda S GraisDirectorNov 2013
Michael F PowellDirectorNov 2013
Nina L KjellsonDirectorNov 2013
Pratik F ShahDirectorNov 2013
Anne M. VanLentDirectorJul 2013
Eckard F. WeberDirectorJul 2013
Franck S. RousseauDirectorJul 2013
Jean-Paul F. CastaigneDirectorJul 2013
Lars F. EkmanDirectorJul 2013
Linda S. GraisDirectorJul 2013
Michael F. PowellDirectorJul 2013
Nina S. KjellsonDirectorJul 2013
Pratik F. ShahDirectorJul 2013
Aaron F. DavidsonDirectorJun 2010
Alex D. ZissonDirectorJun 2010
Brenda D. GavinDirectorJun 2010
David J. DrutzDirectorJun 2010
Donald F. CorcoranDirectorJun 2010
Jean-Paul K. CastaigneDirectorJun 2010
Vipin K. GargDirectorJun 2010